Peloton Therapeutics

May 24, 2019

Time to restock big pharma’s leaking pipeline

The number of late-stage assets in the hands of the industry’s behemoths is shrinking, and this can only put more pressure on companies to do deals.

May 21, 2019

Merck sees potential in Peloton

Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively little clinical data.

April 10, 2019

Venture funding slowdown continues in first quarter of 2019

Venture funding drops again, but there’s no need to panic yet.

October 18, 2016

Peloton Therapeutics

Time to restock big pharma’s leaking pipeline

Merck sees potential in Peloton

Venture funding slowdown continues in first quarter of 2019

Biotech venture funding shrinks as post-boom shape emerges

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Esmo 2019 preview – Parps on parade

Alzheimer's setbacks have prompted $39bn of market cap losses this year

Should the diabetes development road end for Sanofi?

Six burning Otezla questions

The PCSK9 wars continue, but at what cost?